Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tazemetostat Expanded Access Program for Adults With Solid Tumors

Trial Profile

Tazemetostat Expanded Access Program for Adults With Solid Tumors

Status: Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 25 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tazemetostat (Primary)
  • Indications Carcinoma; Chordoma; Ovarian cancer; Sarcoma; Solid tumours; Thoracic neoplasms
  • Focus Expanded access; Therapeutic Use
  • Sponsors Epizyme

Most Recent Events

  • 05 Jul 2023 Status changed from recruiting to completed.
  • 16 Aug 2021 Status changed from suspended to recruiting.
  • 18 Mar 2019 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top